Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence

Aravind Sosale,1 Banshi Saboo,2 Bhavana Sosale11Diacon Hospital, Bangalore, 2Dia Care (Diabetes Care and Hormone Clinic), Ahmedabad, IndiaAbstract: Diabetes mellitus (DM) is one of the most dreaded metabolic disorders in the world today. It is the leading cause of morbidity and mortality, and plays...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sosale A, Saboo B, Sosale B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/3e5896703be74761849e4f025211a96c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3e5896703be74761849e4f025211a96c
record_format	dspace
spelling	oai:doaj.org-article:3e5896703be74761849e4f025211a96c2021-12-02T02:30:57ZSaroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence1178-7007https://doaj.org/article/3e5896703be74761849e4f025211a96c2015-04-01T00:00:00Zhttp://www.dovepress.com/saroglitazar-for-the-treatment-of-hypertriglyceridemia-in-patients-wit-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Aravind Sosale,1 Banshi Saboo,2 Bhavana Sosale11Diacon Hospital, Bangalore, 2Dia Care (Diabetes Care and Hormone Clinic), Ahmedabad, IndiaAbstract: Diabetes mellitus (DM) is one of the most dreaded metabolic disorders in the world today. It is the leading cause of morbidity and mortality, and plays a cardinal role in quality of life and health economics. DM is associated with a high prevalence of microvascular and macrovascular complications. DM is a very important cardiovascular (CV) risk factor. Cardiovascular disease (CVD) has been implicated as the prime cause of mortality and morbidity in patients with DM. Hence, treatment of DM goes beyond glycemic control, and demands a multidisciplinary approach that comprehensively targets risk factors inherent in CV events. Lipid abnormalities are undoubtedly common in patients with DM, and they contribute to an increased risk of CVD. A high-risk lipid profile, termed atherogenic dyslipidemia of diabetes (ADD), is known to occur in patients with DM. The use of lipid-lowering agents, a quintessential part of the multifactorial risk factor approach, is a crucial intervention to minimize diabetes-related complications. In this article, we discuss the role of peroxisome proliferator activator receptor (PPAR) alpha/gamma (α/γ) agonist, saroglitazar, in the management of ADD. While statins are irrefutably the first line of drugs for dyslipidemia management in patients with residual CV risk while on a statin, PPAR α/γ agonists have been found to be of substantial benefit. Data from the PRESS I–VI clinical trials testify to the fact that saroglitazar and fibrates have similar efficacy in reducing triglycerides and improving high-density lipoprotein. The ancillary benefit of improved glycemic control, without the weight gain of PPAR γ agonists, is an added advantage. Reduction in ADD, improved glycemic control, efficacy at par with fibrates, and an acceptable safety profile form the grounds on which this group of PPAR α/γ agonists, with their novel mechanism, holds a promising future in the management of diabetic dyslipidemia.Keywords: diabetes mellitus, dyslipidemia, cardiovascular disease, atherosclerosis, PPAR α/γ agonistsSosale ASaboo BSosale BDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 189-196 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Sosale A Saboo B Sosale B Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
description	Aravind Sosale,1 Banshi Saboo,2 Bhavana Sosale11Diacon Hospital, Bangalore, 2Dia Care (Diabetes Care and Hormone Clinic), Ahmedabad, IndiaAbstract: Diabetes mellitus (DM) is one of the most dreaded metabolic disorders in the world today. It is the leading cause of morbidity and mortality, and plays a cardinal role in quality of life and health economics. DM is associated with a high prevalence of microvascular and macrovascular complications. DM is a very important cardiovascular (CV) risk factor. Cardiovascular disease (CVD) has been implicated as the prime cause of mortality and morbidity in patients with DM. Hence, treatment of DM goes beyond glycemic control, and demands a multidisciplinary approach that comprehensively targets risk factors inherent in CV events. Lipid abnormalities are undoubtedly common in patients with DM, and they contribute to an increased risk of CVD. A high-risk lipid profile, termed atherogenic dyslipidemia of diabetes (ADD), is known to occur in patients with DM. The use of lipid-lowering agents, a quintessential part of the multifactorial risk factor approach, is a crucial intervention to minimize diabetes-related complications. In this article, we discuss the role of peroxisome proliferator activator receptor (PPAR) alpha/gamma (α/γ) agonist, saroglitazar, in the management of ADD. While statins are irrefutably the first line of drugs for dyslipidemia management in patients with residual CV risk while on a statin, PPAR α/γ agonists have been found to be of substantial benefit. Data from the PRESS I–VI clinical trials testify to the fact that saroglitazar and fibrates have similar efficacy in reducing triglycerides and improving high-density lipoprotein. The ancillary benefit of improved glycemic control, without the weight gain of PPAR γ agonists, is an added advantage. Reduction in ADD, improved glycemic control, efficacy at par with fibrates, and an acceptable safety profile form the grounds on which this group of PPAR α/γ agonists, with their novel mechanism, holds a promising future in the management of diabetic dyslipidemia.Keywords: diabetes mellitus, dyslipidemia, cardiovascular disease, atherosclerosis, PPAR α/γ agonists
format	article
author	Sosale A Saboo B Sosale B
author_facet	Sosale A Saboo B Sosale B
author_sort	Sosale A
title	Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
title_short	Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
title_full	Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
title_fullStr	Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
title_full_unstemmed	Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
title_sort	saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/3e5896703be74761849e4f025211a96c
work_keys_str_mv	AT sosalea saroglitazarforthetreatmentofhypertriglyceridemiainpatientswithtype2diabetescurrentevidence AT saboob saroglitazarforthetreatmentofhypertriglyceridemiainpatientswithtype2diabetescurrentevidence AT sosaleb saroglitazarforthetreatmentofhypertriglyceridemiainpatientswithtype2diabetescurrentevidence
_version_	1718402402560770048

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence

Ejemplares similares